
## **Involvement of patients in the French HTA process**





## Role of patients in the French HTA process





Possible request for input from national patients

The HAS is creating a pool of patients



### **National Patient Associations**

In the EAP process and the common clinical appraisal procedure for reimbursement:

### Input from national patient advocacy groups

Questionnaire – Common procedure for reimbursement

- Impacts of the disease on quality of life (patients, relatives and caregivers)
- Currently available treatments (excluding the medicine under evaluation)
- The medicine under evaluation
  - Your comments on the indication requested by the laboratory
  - If you have experience with the medicine under study (otherwise, move to the next section), Advantages/ Disadvantages observed when using the medicine under study compared to other treatments currently used
  - If you have no experience with the medicine under evaluation: what are your expectations and concerns for the medecine under study?

#### Questionnaire - Early Access Program

- Your position regarding the criteria for early access authorisation
- Your position on the data to be collected by patients if early access to the medicine is granted
  - The data and information that are important to collect
  - Your opinion on the therapeutic use protocol Data collection



## Information available to PAG


Stage of the HTA evaluation procedure (National and European)	Type of PAG Contribution	Documents available for patient organizations
CSC & Early Dating	<ul> <li>Will French patients have the opportunity to take part in a JSC?</li> </ul>	No element planned at the national level
JCA & Early Access Pre-Marketing Authorization	<ul> <li>The HAS continues to take the opinion of French patient associations via:         <ul> <li>Written contribution,</li> <li>Audition possible</li> <li>+/- comments on the therapeutic use protocol and data collection</li> </ul> </li> </ul>	Nothing new
JCA & Early Access Post-Marketing Authorization	<ul> <li>The HAS continues to take the opinion of French patient associations via:         <ul> <li>Written contribution</li> <li>Audition possible</li> </ul> </li> </ul>	Patient associations will eventually have the JCAR (in French?) and the file submitted by the company (in English)
JCA & Reimbursement Request (excluding EAP)	<ul> <li>The HAS continues to take the opinion of French patient associations via:</li> <li>Written contribution</li> </ul>	Patient associations will eventually have the JCAR (in French?) and the file submitted by the company (in English)

# French patients and medical experts are involved in the French HTA process



**OR** 

HAS Early dialog at the national level



**Consultation of French medical experts** 

